Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis

Yunfei Zhou, Song Li, Yi P. Hu, Jing Wang, Jennie Hauser, Alexis N. Conway, Michelle A. Vinci, Lisa Humphrey, Elizabeth Zborowska, James K.V. Willson, Michael G. Brattain

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Coexpression of the epidermal growth factor receptor (EGFR) family receptors is found in a subset of colon cancers, which may cooperatively promote cancer cell growth and survival, as heterodimerization is known to provide for diversification of signal transduction. Recently, efforts have been made to develop novel 4-anilinoquinazoline and pyridopyrimidine derivatives to inhibit EGFR and ErbB2 kinases simultaneously. In this study, we tested the efficacy of a novel reversible dual inhibitor GW572016 compared with the selective EGFR and ErhB2 tyrosine kinase inhibitors (TKI) AG1478 and AG879 and their combination, using the human colon adenocarcinoma GEO mode. GEO cells depend on multiple ErbB receptors for aberrant growth. A synergistic effect on inhibition of cell proliferation associated with induction of apoptosis was observed from the combination of AG1478 and AG879. Compared with AG1478 or AG879, the single TKI compound GW572016 was a more potent inhibitor of GEO cell proliferation and was able to induce apoptosis at lower concentrations. Western blot analysis revealed that AG1478 and AG879 were unable to suppress both EGFR and ErbB2 activation as well as the downstream mitogen-activated protein kinase (MAPK) and AKT pathways as single agents. In contrast, GW572016 suppressed the activation of EGFR, ErbB2, MAPK, and AKT in a concentration-dependent manner. Finally, in vivo studies showed that GW572016 treatment efficiently blocked GEO xenograft growth at a dose range of 30 to 200 mg/kg with a twice-daily schedule. In summary, our study indicates that targeting both EGFR and ErbB2 simultaneously could enhance therapy over that of single agents directed at EGFR or ErbB2 in cancers that can be identified as being primarily heterodimer-dependent.

Original languageEnglish (US)
Pages (from-to)404-411
Number of pages8
JournalCancer Research
Volume66
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Colon
Apoptosis
Carcinoma
Mitogen-Activated Protein Kinases
Growth
Cell Proliferation
lapatinib
Heterografts
Colonic Neoplasms
Signal Transduction
Neoplasms
Cell Survival
Appointments and Schedules
Adenocarcinoma
Western Blotting
tyrphostin AG 1478
AG-879

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. / Zhou, Yunfei; Li, Song; Hu, Yi P.; Wang, Jing; Hauser, Jennie; Conway, Alexis N.; Vinci, Michelle A.; Humphrey, Lisa; Zborowska, Elizabeth; Willson, James K.V.; Brattain, Michael G.

In: Cancer Research, Vol. 66, No. 1, 01.01.2006, p. 404-411.

Research output: Contribution to journalArticle

Zhou, Y, Li, S, Hu, YP, Wang, J, Hauser, J, Conway, AN, Vinci, MA, Humphrey, L, Zborowska, E, Willson, JKV & Brattain, MG 2006, 'Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis', Cancer Research, vol. 66, no. 1, pp. 404-411. https://doi.org/10.1158/0008-5472.CAN-05-2506
Zhou, Yunfei ; Li, Song ; Hu, Yi P. ; Wang, Jing ; Hauser, Jennie ; Conway, Alexis N. ; Vinci, Michelle A. ; Humphrey, Lisa ; Zborowska, Elizabeth ; Willson, James K.V. ; Brattain, Michael G. / Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. In: Cancer Research. 2006 ; Vol. 66, No. 1. pp. 404-411.
@article{8c0228e64efb458dabb914c20b52221e,
title = "Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis",
abstract = "Coexpression of the epidermal growth factor receptor (EGFR) family receptors is found in a subset of colon cancers, which may cooperatively promote cancer cell growth and survival, as heterodimerization is known to provide for diversification of signal transduction. Recently, efforts have been made to develop novel 4-anilinoquinazoline and pyridopyrimidine derivatives to inhibit EGFR and ErbB2 kinases simultaneously. In this study, we tested the efficacy of a novel reversible dual inhibitor GW572016 compared with the selective EGFR and ErhB2 tyrosine kinase inhibitors (TKI) AG1478 and AG879 and their combination, using the human colon adenocarcinoma GEO mode. GEO cells depend on multiple ErbB receptors for aberrant growth. A synergistic effect on inhibition of cell proliferation associated with induction of apoptosis was observed from the combination of AG1478 and AG879. Compared with AG1478 or AG879, the single TKI compound GW572016 was a more potent inhibitor of GEO cell proliferation and was able to induce apoptosis at lower concentrations. Western blot analysis revealed that AG1478 and AG879 were unable to suppress both EGFR and ErbB2 activation as well as the downstream mitogen-activated protein kinase (MAPK) and AKT pathways as single agents. In contrast, GW572016 suppressed the activation of EGFR, ErbB2, MAPK, and AKT in a concentration-dependent manner. Finally, in vivo studies showed that GW572016 treatment efficiently blocked GEO xenograft growth at a dose range of 30 to 200 mg/kg with a twice-daily schedule. In summary, our study indicates that targeting both EGFR and ErbB2 simultaneously could enhance therapy over that of single agents directed at EGFR or ErbB2 in cancers that can be identified as being primarily heterodimer-dependent.",
author = "Yunfei Zhou and Song Li and Hu, {Yi P.} and Jing Wang and Jennie Hauser and Conway, {Alexis N.} and Vinci, {Michelle A.} and Lisa Humphrey and Elizabeth Zborowska and Willson, {James K.V.} and Brattain, {Michael G.}",
year = "2006",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-05-2506",
language = "English (US)",
volume = "66",
pages = "404--411",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis

AU - Zhou, Yunfei

AU - Li, Song

AU - Hu, Yi P.

AU - Wang, Jing

AU - Hauser, Jennie

AU - Conway, Alexis N.

AU - Vinci, Michelle A.

AU - Humphrey, Lisa

AU - Zborowska, Elizabeth

AU - Willson, James K.V.

AU - Brattain, Michael G.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Coexpression of the epidermal growth factor receptor (EGFR) family receptors is found in a subset of colon cancers, which may cooperatively promote cancer cell growth and survival, as heterodimerization is known to provide for diversification of signal transduction. Recently, efforts have been made to develop novel 4-anilinoquinazoline and pyridopyrimidine derivatives to inhibit EGFR and ErbB2 kinases simultaneously. In this study, we tested the efficacy of a novel reversible dual inhibitor GW572016 compared with the selective EGFR and ErhB2 tyrosine kinase inhibitors (TKI) AG1478 and AG879 and their combination, using the human colon adenocarcinoma GEO mode. GEO cells depend on multiple ErbB receptors for aberrant growth. A synergistic effect on inhibition of cell proliferation associated with induction of apoptosis was observed from the combination of AG1478 and AG879. Compared with AG1478 or AG879, the single TKI compound GW572016 was a more potent inhibitor of GEO cell proliferation and was able to induce apoptosis at lower concentrations. Western blot analysis revealed that AG1478 and AG879 were unable to suppress both EGFR and ErbB2 activation as well as the downstream mitogen-activated protein kinase (MAPK) and AKT pathways as single agents. In contrast, GW572016 suppressed the activation of EGFR, ErbB2, MAPK, and AKT in a concentration-dependent manner. Finally, in vivo studies showed that GW572016 treatment efficiently blocked GEO xenograft growth at a dose range of 30 to 200 mg/kg with a twice-daily schedule. In summary, our study indicates that targeting both EGFR and ErbB2 simultaneously could enhance therapy over that of single agents directed at EGFR or ErbB2 in cancers that can be identified as being primarily heterodimer-dependent.

AB - Coexpression of the epidermal growth factor receptor (EGFR) family receptors is found in a subset of colon cancers, which may cooperatively promote cancer cell growth and survival, as heterodimerization is known to provide for diversification of signal transduction. Recently, efforts have been made to develop novel 4-anilinoquinazoline and pyridopyrimidine derivatives to inhibit EGFR and ErbB2 kinases simultaneously. In this study, we tested the efficacy of a novel reversible dual inhibitor GW572016 compared with the selective EGFR and ErhB2 tyrosine kinase inhibitors (TKI) AG1478 and AG879 and their combination, using the human colon adenocarcinoma GEO mode. GEO cells depend on multiple ErbB receptors for aberrant growth. A synergistic effect on inhibition of cell proliferation associated with induction of apoptosis was observed from the combination of AG1478 and AG879. Compared with AG1478 or AG879, the single TKI compound GW572016 was a more potent inhibitor of GEO cell proliferation and was able to induce apoptosis at lower concentrations. Western blot analysis revealed that AG1478 and AG879 were unable to suppress both EGFR and ErbB2 activation as well as the downstream mitogen-activated protein kinase (MAPK) and AKT pathways as single agents. In contrast, GW572016 suppressed the activation of EGFR, ErbB2, MAPK, and AKT in a concentration-dependent manner. Finally, in vivo studies showed that GW572016 treatment efficiently blocked GEO xenograft growth at a dose range of 30 to 200 mg/kg with a twice-daily schedule. In summary, our study indicates that targeting both EGFR and ErbB2 simultaneously could enhance therapy over that of single agents directed at EGFR or ErbB2 in cancers that can be identified as being primarily heterodimer-dependent.

UR - http://www.scopus.com/inward/record.url?scp=31544457665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544457665&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-2506

DO - 10.1158/0008-5472.CAN-05-2506

M3 - Article

C2 - 16397255

AN - SCOPUS:31544457665

VL - 66

SP - 404

EP - 411

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 1

ER -